First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor Dapansutrile

July 11, 2024 /PRNewswire/ -- Olatec Therapeutics, Inc. ( Olatec ), a leader in the emerging class of specific NLRP3 inhibitors, announced patients with type 2 diabetes mellitus (T2D) and diabetes-related complications (the DAPAN-DIA Study ) are being enrolled in a Phase 2 clinical trial in Basel, Switzerland.

The release as fetched from its publisher. olatec.com ↗